These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 9860780)

  • 1. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators.
    Cannon CP; Gibson CM; McCabe CH; Adgey AA; Schweiger MJ; Sequeira RF; Grollier G; Giugliano RP; Frey M; Mueller HS; Steingart RM; Weaver WD; Van de Werf F; Braunwald E
    Circulation; 1998 Dec 22-29; 98(25):2805-14. PubMed ID: 9860780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators.
    Van de Werf F; Cannon CP; Luyten A; Houbracken K; McCabe CH; Berioli S; Bluhmki E; Sarelin H; Wang-Clow F; Fox NL; Braunwald E
    Am Heart J; 1999 May; 137(5):786-91. PubMed ID: 10220625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B Investigators.
    Gibson CM; Cannon CP; Murphy SA; Adgey AA; Schweiger MJ; Sequeira RF; Grollier G; Fox NL; Berioli S; Weaver WD; Van de Werf F; Braunwald E
    Am J Cardiol; 1999 Nov; 84(9):976-80. PubMed ID: 10569649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial.
    Cannon CP; McCabe CH; Gibson CM; Ghali M; Sequeira RF; McKendall GR; Breed J; Modi NB; Fox NL; Tracy RP; Love TW; Braunwald E
    Circulation; 1997 Jan; 95(2):351-6. PubMed ID: 9008448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage.
    Giugliano RP; McCabe CH; Antman EM; Cannon CP; Van de Werf F; Wilcox RG; Braunwald E;
    Am Heart J; 2001 May; 141(5):742-50. PubMed ID: 11320361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of a weight-adjusted dose of TNK-tissue plasminogen activator.
    Wang-Clow F; Fox NL; Cannon CP; Gibson CM; Berioli S; Bluhmki E; Danays T; Braunwald E; Van De Werf F; Stump DC
    Am Heart J; 2001 Jan; 141(1):33-40. PubMed ID: 11136484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction.
    Dunn CJ; Goa KL
    Am J Cardiovasc Drugs; 2001; 1(1):51-66. PubMed ID: 14728052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
    Smalling RW; Bode C; Kalbfleisch J; Sen S; Limbourg P; Forycki F; Habib G; Feldman R; Hohnloser S; Seals A
    Circulation; 1995 Jun; 91(11):2725-32. PubMed ID: 7758177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [An angiographic trial to evaluate the efficacy and safety of tenecteplase in Chinese patients with acute myocardial infarction].
    Liang F; Wang LZ; Hu DY; Shi XB; Wei JP; Zhao H; Wang L; Jia SQ; Wang HY; Liu RH; Chen YD; Lu YL
    Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Jun; 37(6):514-7. PubMed ID: 19927632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase.
    Szabo S; Letsch R; Ehlers R; Walter T; Kazmaier S; Helber U; Hoffmeister HM
    Thromb Res; 2002 Apr; 106(2):113-9. PubMed ID: 12182909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.
    Bode C; Smalling RW; Berg G; Burnett C; Lorch G; Kalbfleisch JM; Chernoff R; Christie LG; Feldman RL; Seals AA; Weaver WD
    Circulation; 1996 Sep; 94(5):891-8. PubMed ID: 8790022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA.
    Van de Werf F; Barron HV; Armstrong PW; Granger CB; Berioli S; Barbash G; Pehrsson K; Verheugt FW; Meyer J; Betriu A; Califf RM; Li X; Fox NL;
    Eur Heart J; 2001 Dec; 22(24):2253-61. PubMed ID: 11728145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial.
    Antman EM; Louwerenburg HW; Baars HF; Wesdorp JC; Hamer B; Bassand JP; Bigonzi F; Pisapia G; Gibson CM; Heidbuchel H; Braunwald E; Van de Werf F
    Circulation; 2002 Apr; 105(14):1642-9. PubMed ID: 11940541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patency trials with reteplase (r-PA): what do they tell us?
    Bode C; Nordt TK; Peter K; Smalling RW; Runge MS; Kübler W
    Am J Cardiol; 1996 Dec; 78(12A):16-9. PubMed ID: 8990406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial.
    Giugliano RP; Roe MT; Harrington RA; Gibson CM; Zeymer U; Van de Werf F; Baran KW; Hobbach HP; Woodlief LH; Hannan KL; Greenberg S; Miller J; Kitt MM; Strony J; McCabe CH; Braunwald E; Califf RM;
    J Am Coll Cardiol; 2003 Apr; 41(8):1251-60. PubMed ID: 12706917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative fibrinolytic activity of front-loaded alteplase and the single-bolus mutants tenecteplase and lanoteplase during treatment of acute myocardial infarction.
    Al-Shwafi KA; de Meester A; Pirenne B; Col JJ
    Am Heart J; 2003 Feb; 145(2):217-25. PubMed ID: 12595837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal thrombolytic strategies for acute myocardial infarction--bolus administration.
    McMechan SR; Adgey AA
    QJM; 1998 Nov; 91(11):719-25. PubMed ID: 10024933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
    Cannon CP; McCabe CH; Henry TD; Schweiger MJ; Gibson RS; Mueller HS; Becker RC; Kleiman NS; Haugland JM; Anderson JL
    J Am Coll Cardiol; 1994 Apr; 23(5):993-1003. PubMed ID: 8144799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction.
    Modi NB; Eppler S; Breed J; Cannon CP; Braunwald E; Love TW
    Thromb Haemost; 1998 Jan; 79(1):134-9. PubMed ID: 9459338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy.
    Serebruany VL; Malinin AI; Callahan KP; Binbrek A; Van De Werf F; Alexander JH; Granger CB; Gurbel PA;
    Am Heart J; 2003 Apr; 145(4):636-42. PubMed ID: 12679759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.